| Market Cap | 1.49B | P/E | 35.39 | EPS this Y | -44.30% | Ern Qtrly Grth | -14.30% |
| Income | 42.46M | Forward P/E | 39.50 | EPS next Y | - | 50D Avg Chg | 3.00% |
| Sales | 333.02M | PEG | 2.56 | EPS past 5Y | 15.92% | 200D Avg Chg | 9.00% |
| Dividend | N/A | Price/Book | 4.04 | EPS next 5Y | 17.00% | 52W High Chg | -1.00% |
| Recommedations | 3.00 | Quick Ratio | 2.22 | Shares Outstanding | 43.83M | 52W Low Chg | 45.00% |
| Insider Own | 1.34% | ROA | 10.35% | Shares Float | 41.15M | Beta | 0.23 |
| Inst Own | 90.92% | ROE | 12.19% | Shares Shorted/Prior | 4.24M/3.43M | Price | 33.97 |
| Gross Margin | 56.56% | Profit Margin | 12.75% | Avg. Volume | 676,914 | Target Price | - |
| Oper. Margin | 22.70% | Earnings Date | May 4 | Volume | 5,627,450 | Change | 0.00% |
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests for Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, isothermal reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
| HC Wainwright & Co. | Neutral | Jul 8, 22 |
| HC Wainwright & Co. | Buy | Feb 7, 22 |
| HC Wainwright & Co. | Buy | Nov 15, 21 |
| HC Wainwright & Co. | Buy | Aug 9, 21 |
| HC Wainwright & Co. | Buy | May 10, 21 |
| HC Wainwright & Co. | Buy | Feb 24, 21 |
| HC Wainwright & Co. | Buy | Feb 8, 21 |
| HC Wainwright & Co. | Buy | Nov 16, 20 |
| HC Wainwright & Co. | Buy | Jul 27, 20 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Anderson James M. | Director Director | Jan 06 | Option | 20.38 | 8,500 | 173,230 | 28,224 | 01/09/23 |
| Kenny John P. | Chief Executive Offi.. Chief Executive Officer | Jun 24 | Option | 10.1 | 74,996 | 757,460 | 326,568 | 06/28/22 |
| Kenny John P. | Chief Executive Offi.. Chief Executive Officer | Jun 24 | Sell | 30.2 | 74,996 | 2,264,879 | 265,131 | 06/28/22 |
| Kenny John P. | Chief Executive Offi.. Chief Executive Officer | Jun 22 | Option | 13.03 | 64,607 | 841,829 | 285,087 | 06/24/22 |
| Kenny John P. | Chief Executive Offi.. Chief Executive Officer | Jun 22 | Sell | 29.85 | 64,607 | 1,928,519 | 265,131 | 06/24/22 |
| Kitzmiller Andrew S. | EVP & CFO EVP & CFO | Feb 25 | Buy | 24.8675 | 4,028 | 100,166 | 11,528 | 02/28/22 |
| WELTZIEN LOURDES | EVP, Life Science EVP, Life Science | Feb 15 | Option | 14.48 | 20,000 | 289,600 | 103,048 | 02/17/22 |
| WELTZIEN LOURDES | EVP, Life Science EVP, Life Science | Feb 15 | Sell | 25.6 | 20,000 | 512,000 | 83,048 | 02/17/22 |
| PHILLIPS DAVID | Director Director | Jan 12 | Option | 18.54 | 7,500 | 139,050 | 14,045 | 01/14/22 |
| Kenny John P. | Chief Executive Offi.. Chief Executive Officer | Feb 10 | Option | 12.3 | 66,134 | 813,448 | 320,464 | 02/10/21 |
| Kenny John P. | Chief Executive Offi.. Chief Executive Officer | Feb 10 | Sell | 29.86 | 68,288 | 2,039,080 | 252,176 | 02/10/21 |